11201803218P

Text of the abstract

The present disclosure provides methods of treating a lysosomal storage disorder in a mammal which method comprises administering AAV particles encoding a polypeptide directly to the central nervous system of the mammal in conjunction with administering at least two immunosuppressive agents such as cyclosporine and mycophenolate mofitil (MMF). AAV particles may be delivered by direct injection into the brain, spinal cord, cerebral spinal fluid, or a portion thereof of said mammal.